Medtech innovator Bone Health Technologies (BHT), Redwood City, CA, recently announced the company has been awarded a 5th patent for Osteoboost—the 1st and only US Food & Drug Administration–cleared prescription medical device to treat osteopenia.
The patent, titled ‘Wearable Apparatus for the Treatment or Prevention of Osteopenia and Osteoporosis,” describes the company’s unique formula of precision-targeted vibration therapy, clinically proven to reduce the loss of bone density and strength in the lumbar spine in postmenopausal women.
“More than half of the devastating, life-altering fragility fractures happen to the 52 million patients with osteopenia who, prior to Osteoboost, had limited treatment options,” said Laura Yecies, CEO at BHT. “Early intervention at the osteopenia stage to stop the loss of bone is critical to enabling women to stay strong, active, and fracture-free as they age. This patent recognizes the unique approach of our vibration therapy, and will further help us bring Osteoboost to market later this year.”
